PepsiCo (NYSE: PEP ) will report earnings on Wednesday. Here's what you need to watch for in the company's results.
Great expectations
The first issue that needs to be addressed is whether the beverage and snack food giant met Wall Street's expectations. Analysts peg profits for PepsiCo at $1.19 per share this quarter. PepsiCo booked earnings per share of $1.12 in the same quarter last year, so the company is expecting an improvement in profit growth. PepsiCo reported approximately $16 billion in sales for the second quarter of last year, and $65 billion for the full-year 2012.
Revenue growth
PepsiCo's first-quarter 2013 overall organic net revenues grew 4.4%. Even though PepsiCo has felt the effects of a recent pullback in domestic soda sales, about 65% of the company's beverage business comes from non-carbonated offerings, a segment that shows real growth potential, notably in developed markets.
In relatively untapped emerging markets, both PepsiCo and rival Coca-Cola are spending billions of dollars�in the pursuit of vigorous growth. For example, India represents one of the last untouched markets for cola companies. As a result, Pepsi and Coke are fighting tooth and nail to gain market share for their namesake brands. Indian consumers sip 14 servings of soft drinks annually, while Americans guzzle more than 28 times as much cola.�Yet the Asian nation's population is nearly four times that of the U.S.
Best Asian Stocks To Invest In Right Now: Giant Interactive Group Inc (GA)
Giant Interactive Group Inc. (Giant Interactive), incorporated on July 26, 2006, is an online game developer and operator in China. The Company focuses on massively multiplayer online role playing games (MMORPG) that are played through networked game servers, in which a number of players are able to simultaneously connect and interact. The Company operates 11 online games, among which nine are self-developed, including the five games in the Zheng Tu (ZT) Online Series. As of December 31, 2010, its game development team consisted of 934 members, which includes product development and enhancement teams for each of its MMORPG and multiplayer online (MMO) games.
In January 2010, the Company acquired China operation licenses for Elsword and Allods Online, two three dimensional (3D) MMORPGs. In November 2010, the Company acquired Julun Network. On December 6, 2010, Zhengtu Information, Giant Network and Shanghai Juyan Network Technology jointly established Beijing Huayi Juren Information Technology Co., Ltd with 51%, 34% and 15% interest, respectively. On December 31, 2010, Zhengtu Information sold its 51% interest in Huayi Juren Information to Huayi Brothers Media Corporation. In May 2010, the Company acquired Snow Wolf.
The Company has built nationwide distribution and marketing networks to sell and market its prepaid game cards and game points. As of December 31, 2010, its distribution network consisted of more than 130 non-exclusive regional distributors and reached over 96,000 retail outlets, including Internet cafes, software stores, supermarkets, bookstores, newspaper stands and convenience stores located throughout China. The Company also sells game points through its official game Website. The Company generates its revenues from licensing of its games to third party operators in other territories, including Hong Kong, Macau, Taiwan, Malaysia, Singapore, Vietnam, Russia and other Russian speaking territories. In addition, it has also licensed its ZT Online Green Edition to! Shenzhen Tencent Computer Systems Company Limited (Tencent), on a non-exclusive basis for operation of such game on Tencent�� QQ game platform in China.
ZT Online
ZT Online is a two-dimensional, online role-playing game set in ancient China, and was the first game that was wholly developed by its internal product development team. ZT Online players assume one of five different roles, including soldiers and magicians, in 10 different kingdoms. In order to play ZT Online, players must log into one of multiple shards, or independent copies of the game world. Players can only interact with other players in his or her respective shard at any given time, and its technology enables players to travel among the different shards. The Company has developed technology for use in ZT Online that allows up to 40,000 players to play together in a single shard at any given time. ZT Online is free of charge to play. Players may purchase physical or virtual prepaid game cards and game points on its game Website or from Internet cafes and other distribution points, which allow their characters to obtain gold coins, one of the currencies used in the ZT Online game. Players may also earn silver coins for their characters when they fulfill tasks or adventures in the game world.
The game has gold coin vouchers, which are offered both as a salary to players who meet certain requirements and as a reward in connection with certain of its promotions. Players may trade silver coins for gold coins, and vice-versa, inside the game. Neither gold coins, gold coin vouchers, nor silver coins may be used by players to purchase any items or services outside of the ZT Online game. ZT Online allows players to purchase a range of virtual items and services for their characters using their gold and/or silver coins. These include weapons, clothing, pets, ceremonies and rites, and others. Weapons may be repaired or replaced by purchases of certain in-game raw materials or by payment of additional gold or! silver c! oins. ZT Online offers a play experience, where players can choose to enter the game 24 hours a day, seven days a week. ZT Online can be accessed from any location with an Internet connection. It has licensed ZT Online to Lager Network for operation in Hong Kong, Macau, Taiwan, Malaysia and Singapore, licensed ZT Online to VinaGame for operation in Vietnam, and licensed ZT Online to Atrum Nival for operation in the Russia and other Russian speaking territories.
ZT Online PTP
ZT Online PTP is pay-to-play MMORPG game developed by the Company, and is based on the ZT Online free-to-play game. As in ZT Online, players assume one of five different roles in 10 different kingdoms. ZT Online PTP also requires players to log into one of multiple shards, while enabling players to travel between different shards. ZT Online PTP requires players to pay to play the game by purchasing physical or virtual prepaid game cards on its game Website or from Internet cafes and other distribution points. ZT Online PTP shares the same graphics and system requirements as ZT Online.
Giant Online
Giant Online is a military-themed MMORPG. Giant Online players may assume one of 14 different roles, such as detectives and spies. As with ZT Online, the game world in Giant Online is divided into a number of regions. Each player must guide his or her character to develop skills and cooperate with other players to fight against players from other regions. Players can equip their characters with a range of modern weaponry. Apart from waging war, characters can also engage in forms of in-game social interaction, such as friendship and even romance. Giant Online enables players, and groups of players, to purchase a range of virtual items and services. These virtual items and services include weapons, vehicles and pets. Giant Online is a 2.5 dimensional game, the background and items in the game are depicted three dimensionally, while the characters are depicted two dimensionally.
King of! Kings IIIK III is a three-dimensional online role-playing experience set in a European-style magical world. Players assume the roles of K III heroes as they explore across a virtual world of forests and medieval cities and castles. K III is the third episode of the King of Kings series of MMORPGs.
My Sweetie
My Sweetie is a 2.5D free-to-play casual MMO game, which allows players to create virtual characters, raise virtual pets on their personal computer desktops and go online to interact with other virtual pet-owners. My Sweetie is the game developed pursuant to its Win@Giant program.
XT Online is a 2.5D ancient Chinese martial arts MMORPG that was developed by Snow Wolf, a game development studio. XT Online enables users to practice different schools or styles of martial arts with the goal of becoming a master, while focusing on brotherhood and trust-building with other martial artists. The Golden Land is a free-to-play medieval strategy browser game, which was developed by Juhe Network, one of its 51% owned game development studios. ZT Online II is an internally-developed free-to-play 2D sequel to its game ZT Online. ZT Online II was developed by an internal studio that it is reorganizing into Jujia Network, one of its 51% owned game development studios.
Dragon Soul is an internally developed 3D ancient Chinese MMORPG developed by Chengdu Jufan Network Technology Co. Ltd. (Jufan Network) one of its 51% owned game development studios. Spirits of the Warriors is a free-to-play 3D MMORPG based on the Three Kingdoms period of ancient Chinese history.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading UP
Giant Interactive Group (NYSE: GA) shot up 12.29 percent to $11.36 after the company received a non-binding proposal to acquire the company for $11.75 per share. - [By Jake L'Ecuyer]
Equities Trading UP
Giant Interactive Group (NYSE: GA) shot up 11.97 percent to $11.34 after the company received a non-binding proposal to acquire the company for $11.75 per share.
Best Asian Stocks To Invest In Right Now: Charter Financial Corp.(CHFN)
Charter Financial Corporation operates as the holding company for CharterBank that provides various banking services to individuals and businesses in Georgia and Alabama. Its deposit products include demand, NOW, and money market accounts; savings deposits; time deposits; checking accounts; and certificates of deposit. The company's loan products comprise commercial real estate loans; one- to four-family residential mortgage loans; construction and development loans; commercial business loans; and consumer loans, such as home equity loans, lines of credit, auto loans, and second mortgage loans. It operates through 16 branch offices located in West Point, LaGrange, Newnan, Carrollton, Bremen, Covington, and Peachtree City, Georgia; and Auburn, Opelika, and Valley, Alabama, as well as through a loan production office located in Norcross, Georgia. The company was founded in 1954 and is based in West Point, Georgia. Charter Financial Corporation operates as a subsidiary of Fir st Charter, MHC.
Advisors' Opinion:- [By Tim Melvin]
I get somewhat amused every day by the thousands of traders who spend all day trying to figure out what the hot stocks like Twitter (TWTR) and Facebook (FB) are going to do every day. Owning stocks like these two banks — or ones I have mentioned before, like ESSA Bancorp (ESSA) and Charter Financial (CHFN) — will be a far more profitable and relaxing endeavor over the next few years.
Top Penny Companies For 2015: RPM International Inc.(RPM)
RPM International Inc., together with its subsidiaries, manufactures, markets, and sells various specialty chemical products to industrial and consumer markets worldwide. The company?s Industrial segment offers waterproofing and institutional roofing systems used in building protection, maintenance, and weatherproofing applications; sealants, tapes, and foams; residential basement waterproofing systems; specialized roofing and building maintenance and related services; specialty industrial adhesives and sealants; and concrete and masonry additives, and related construction chemicals. It also offers polymer flooring systems, and offshore and marine structures; industrial and commercial tile systems; fiberglass reinforced plastic gratings and shapes; heavy-duty corrosion-control coatings, fireproofing products, and containment linings; specialty construction products, including bridge expansion joints, bridge deck and parking deck membranes, curb and channel drains, highway markings, protective coatings, and concrete repairs; and fluorescent colorants and pigments, waterproofing and flooring products, exterior insulating finishing systems, and shellac-based-specialty coatings for industrial and pharmaceutical uses, edible glazes, and food coatings. The company?s Consumer segment provides professional use and do-it-yourself products for a range of consumer applications, including home improvement and personal leisure activities. Its products include coating products; specialty products; deck and fence restoration products; metallic and faux finish coatings; hobby paints and cements; and caulks, sealants, adhesives, insulating foam, spackling, glazing, and other general patch and repair products. The company offers its products under the Carboline, DAP, EUCO, Fibergrate, Flecto, Flowcrete, Hummervoll, Universal Sealants, illbruck, Rust-Oleum, Stonhard, Tremco, Watco, and Zinsser brand names. RPM International was founded in 1947 and is headquarte red in Medina, Ohio.
Advisors' Opinion:- [By abirk]
Spirit's profits are signs of steady growth. Since 2010, Annual passenger revenue and net income have both increased steadily. Spirit generated 24.4% growth in revenue passenger miles (RPM), while the available seat miles (ASM), and grew 24.8%. On the other hand, Delta's mainland division had 8.6 million RPM. �On a revenue basis, Spirit is equivalent to about 3.2% of the total revenue of the combined Delta and US Airways, now part of American Airlines Group (AAL).
- [By Dividends4Life]
The basic materials sector is highly cyclical. It relies on a strong economy to create demand for its raw materials. Since most of its products are considered to be commodities, the sector is sensitive to supply and demand fluctuations, with end-users able to substitute based on price.
Historically, yields in this sector have been on the lower end of the scale. However, with the increased demand for certain raw materials, the stocks in this sector are beginning to see higher yields with increased profitability. In addition, depressed prices on some companies have also boosted yields.
This week, I screened my dividend growth stocks database for Basic Materials companies with a yield above 2.0% and that have increased their dividends for at least 10 consecutive years. The results are presented below:
RPM International Inc. (RPM) makes specialty coatings and products for structural waterproofing and corrosion control, as well as products for the consumer, do-it-yourself and hobby markets. The company has paid a cash dividend to shareholders every year since 1969 and has increased its dividend payments for 40 consecutive years. Yield: 2.3%
Air Products and Chemicals Inc. (APD) is a major producer of industrial gases and electronics and specialty chemicals also has interests in environmental and energy-related businesses. Air Products and Chemicals Inc. is a major producer of industrial gases and electronics and specialty chemicals also has interests in environmental and energy-related businesses. Yield: 2.5%
Nucor Corporation (NUE) is the largest minimill steelmaker in the U.S., Nucor has one of the most diverse product lines of any steelmaker in the Americas. Nucor Corporation is the largest minimill steelmaker in the U.S., Nucor has one of the most diverse product lines of any steelmaker in the Americas. Yield: 2.7%
Alliance Resource Partners LP (ARLP) produces and markets coal primarily to utilities and industr - [By Monica Gerson]
RPM International (NYSE: RPM) is expected to report its Q1 earnings at $0.71 per share on revenue of $1.13 billion.
Zep (NYSE: ZEP) is projected to report its Q4 earnings at $0.24 per share on revenue of $179.09 million.
- [By Laura Brodbeck]
Wednesday
Earnings Expected From: Uniferst (NYSE: UNF), Constellation Brands (NYSE: STZ), RPM International (NYSE: RPM), Global Payments (NYSE: GPN) Economic Releases Expected: German trade balance, German factory orders, Australian retail salesThursday
Best Asian Stocks To Invest In Right Now: Dr. Reddy's Laboratories Ltd(RDY)
Dr. Reddy?s Laboratories Limited, together with its subsidiaries, operates as a pharmaceutical company. It produces finished dosage forms, active pharmaceutical ingredients and intermediates, and biotechnology products. The company also conducts research in the areas of cancer, diabetes, cardiovascular, inflammation, and bacterial infection. In addition, it involves in the contract manufacture generic prescription and over-the-counter products for branded and generic companies in the United States. The company primarily focuses on therapeutic categories of cardiovascular, diabetes management, gastro-intestinal, and pain management. It markets its products in India, the United States, Europe, and the Russian Federation. The company has a co-development and commercialization agreement with Rheoscience A/S for the development and commercialization of Balaglitazone/DRF 2593, a partial PPAR-gamma agonist for the treatment of type 2 diabetes; an agreement with ClinTec Internatio nal for the development of an anti-cancer compound, DRF 1042; collaboration with the National Cancer Institute in Maryland; and an agreement with Argenta Discovery Limited for the joint development and commercialization of a novel approach to the treatment of chronic obstructive pulmonary disease. It also has an agreement with 7TM Pharma for drug discovery collaboration on selected drug targets; and an agreement with GlaxoSmithKline plc to develop and market pharmaceuticals for the treatment of cardiovascular disease, diabetes, oncology, gastroenterology, and pain management. Dr. Reddy?s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.
Advisors' Opinion:- [By Dan Carroll]
The company's generic drug segment should also help push emerging market sales. Abbott markets generic pharmaceuticals outside the U.S. only, and while the division isn't growth-oriented -- sales actually fell around 2% for the quarter -- it provides an entry for the company to push into lucrative new markets such as India, where generics make up the large majority of the country's retail market. The company will face tougher competition in this industry, however: Firms such as India-based Dr. Reddy's (NYSE: RDY ) have also pushed hard into emerging markets lately, and Dr. Reddy's in particular should benefit from its being headquartered in one of the industry's top locales.
- [By Seth Jayson]
Dr. Reddy's Laboratories (NYSE: RDY ) reported earnings on May 14. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q4), Dr. Reddy's Laboratories beat expectations on revenues and beat expectations on earnings per share. - [By Rich Duprey]
Following FDA approval of its abbreviated new drug application, or ANDA,�Dr. Reddy's Laboratories (NYSE: RDY ) announced today that it launched its lamotrigine extended-release tablets, the generic version of GlaxoSmithKline's Lamictal.�
- [By Benjamin Shepherd] We’re now into day 15 of the US government shutdown, as House Republicans stubbornly try to defund Obamacare. No matter what sort of deal is eventually struck, health care costs aren’t likely to come down any time soon. And that’s good news for generic drug makers.
Dr. Reddy’s Laboratories (NYSE: RDY) is one of the biggest players in generic drugs, offering more than 200 off-brand medications in the areas of cardiovascular disease, pain management and oncology, among others. In fact, this India-based company has become one of the largest makers of generics in the world, helping to drive more than 20 percent annual compounded earnings growth at the company over the past decade.
Best Asian Stocks To Invest In Right Now: Diamond Foods Inc.(DMND)
Diamond Foods, Inc., a packaged food company, engages in processing, marketing, and distributing snack products, as well as culinary, in-shell, and ingredient nuts. Its snack products include glazed nuts, roasted and mixed nuts, breakfast trail mix products, microwave popcorn products, and potato and tortilla chips. The company?s culinary nuts comprise shelled nuts, pegboard nuts, and harvest reserve premium nuts. Its in-shell nuts consist of uncracked nuts and mixed nuts; and ingredient/food service products include shelled and processed nuts, and custom-processed nuts. The company offers its products under the Emerald, Pop Secret, Kettle, and Diamond of California brand names. It markets its culinary nuts to individuals, who prepare meals or baked goods at home; and ingredient and food service nuts to food processors, restaurants, bakeries, and food service companies and their suppliers. Diamond Foods, Inc. sells its products directly to retailers, such as national groce ry stores, club stores, mass merchandisers, and drug store chains; and indirectly through wholesale distributors, who serve independent and small regional retail grocery store chains and convenience stores. The company offers its products in the United States, the United Kingdom, Germany, the Netherlands, Spain, Italy, Canada, South Korea, Turkey, and Japan. Diamond Foods, Inc. was founded in 1912 and is based in San Francisco, California.
Advisors' Opinion:- [By Johanna Bennett]
Diamond Foods (DMND) rose 6% to $28.25 after posting fiscal fourth quarter financial results.
General Motors (GM) rose 0.5% to $33.04 after hours Thursday after Standard & Poor’s raised the auto maker’s credit rating back above the investment-grade threshold.
- [By GuruFocus] l Gates sold out his holdings in Diamond Foods, Inc.. His sale prices were between $20.78 and $26.05, with an estimated average price of $23.92.
Here is the complete portfolio of Bill Gates.�
Also check out: Bill Gates Undervalued Stocks Bill Gates Top Growth Companies Bill Gates High Yield stocks, and Stocks that Bill Gates keeps buying
Currently 0.00/512345Rating: 0.0/5 (0 votes)
Subscribe via Email Subscribe RSS Comments Please leave your comment: $(document).ready(function(){ $('#body_login, #watch, #follow, #fake_submit').click(function(){ $.colorbox({innerWidth:"600px", innerHeight:"400px", iframe:false,href:"http://www.gurufocus.com/modules/login_register.php"}); }); });
More GuruFocus Links Latest Guru Picks Value Strategies Warren Buffett Portfolio Ben Graham Net-Net Real Time Picks Buffett-Munger Screener Aggregated Portfolio Undervalued Predictable ETFs, Options Low P/S Companies Insider Trends 10-Year Financials 52-Week Lows Interactive Charts Model Portfolios DCF Calculator RSS Feed Monthly Newsletters The All-In-One Screener Portfolio Tracking Tool - [By Sue Chang]
Diamond Foods (DMND) � is forecast to post a loss of 3 cents a share in the fourth quarter. The stock was upgraded to buy from hold with a price target of $28 at BB&T Capital Markets on Thursday.
Best Asian Stocks To Invest In Right Now: Shire PLC (SHPG)
Shire plc (Shire), incorporated on January 28, 2008, is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. As of December 31, 2012, the Company�� products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), FOSRENOL (lanthanum carbonate), XAGRID (anagrelide hydrochloride), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant) and DERMAGRAFT(Human Fibroblast-Derived Dermal Substitute). As of December 31, 2012, the Company�� products under development included INTUNIV (extended release guanfacine), VYVANSE/VENVANSE (lisdexamfetamine dimesylate), INTUNIV, Guanfacine Carrier Wave, LIALDA (mesalamine)/MEZAVANT (mesalazine), RESOLOR (prucalopride), RESOLOR (prucalopride), SPD 557(M0003), XAGRID, VYVANSE (lisdexamfetamine dimesylate), REPLAGAL (agalsidase alfa), HGT-4510, HGT-2310, HGT-1410, HGT-1110, HGT-3010, and DERMAGRAFT. On January 31, 2012, the United States Food and Drug Administration approved VYVANSE for the maintenance treatment of ADHD in adults. In March 2013, it announced the acquisition Of Premacure AB. In January 2014, Shire Plc sold its DERMAGRAFT assets to Organogenesis Inc. In January 2014, Shire Plc acquired 79.5% interest in ViroPharma Inc.
VANSE/ VENVANSE
VYVANSE is a New Chemical Entity (NCE) and is the pro-drug stimulant for the treatment of ADHD, where the amino acid l-lysine is linked to d-amphetamine. VYVANSE is therapeutically inactive until metabolized in the body. The United Stat! es Food and Drug Administration approved VYVANSE as a once-daily treatment for children aged 6 to 12 with ADHD in February 2007, for adults in April 2008 and for adolescents aged 13 to 17 in November 2010. VYVANSE is available in the United States in six dosage strengths: 20 milligram, 30 milligram, 40 milligram, 50 milligram, 60 milligram and 70 milligram. Health Canada approved VYVANSE for the treatment of ADHD in pediatric patients aged 6 to 12 in February 2009, and for adolescents and adults in November 2010. In April 2012, ANVISA, the Brazilian health authority, granted marketing authorization approval for lisdexamfetamine dimesylate for the treatment of ADHD in children aged 6-12.
ADDERALL XR
ADDERALL XR is an extended release treatment for ADHD, which uses MICROTROL drug delivery technology and is designed to provide once-daily dosing. It is available in 5 milligram, 10 milligram, 15 milligram, 20 milligram, 25 milligram and 30 milligram capsules and can be administered either as a capsule or sprinkled on soft food. The United States Food and Drug Administration has approved ADDERALL XR as a once-daily treatment for children aged 6 to 12 with ADHD, for adults in and for adolescents aged 13 to 17. Teva Pharmaceutical Industries, Ltd. (Teva) and Impax Laboratories, Inc. (Impax) commenced commercial shipment of their authorized generic versions of ADDERALL XR in April and October 2009, respectively. Shire receives royalties from Impax�� sales of authorized generic ADDERALL XR.
INTUNIV
INTUNIV is a selective alpha-2A receptor agonist indicated for the treatment of ADHD. Alpha-2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signalling in the prefrontal cortex (Cell. 2007; 129:397-410). INTUNIV is non-scheduled and has no known potential for abuse or dependence. The United States Food and Drug Administration approved INTUNIV in September 2009, as a once-daily monotherapy treatment of ADHD in children and adolesce! nts aged ! 6 to 17. It is available in 1 milligram, 2 milligram, 3 milligram and 4 milligram tablets.
EQUASYM
Shire has acquired from UCB the worldwide rights (excluding the United States, Canada and Barbados) to EQUASYM (methylphenidate hydrochloride) IR and XL for the treatment of ADHD in children and adolescents aged 6 to 18. At December 31, 2012,EQUASYM XL was commercially available in 10 countries in 10mg, 20mg and 30mg strengths. EQUASYM XL is marketed in Mexico and South Korea under the trade name METADATE CD.
LIALDA/MEZAVANT
LIALDA is indicated for the induction ofmild to moderately active UC and for the maintenance of remission of UC. The addition of the indication for maintenance of remission of ulcerative colitis was approved by Health Canada in February 2011, and by the United States Food and Drug Administration in July 2011. LIALDA is once-daily oral formulation of mesalamine indicated for the induction and maintenance of remission. As of December 31, 2012, LIALDA/MEZAVANT (this product is marketed outside the United States as MEZAVANT) was commercially available in 19 countries either directly or through distributor arrangements.
PENTASA
PENTASA controlled release capsules are approved in the United States (marketed by Shire in the United States and by Ferring outside of the United States) and indicated for the induction of remission and for the treatment of patients with mild to moderately active ulcerative colitis. PENTASA is an ethylcellulose-coated, controlled release capsule formulation designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. PENTASA is available in the United States in 250 milligram and 500 milligram capsules.
RESOLOR
RESOLOR (prucalopride), a 5-HT4 receptor agonists that stimulates gastrointestinal motility and acts primarily on different parts of the lower gastrointestinal tract (enterokinetic). In October 2009, RESOLOR was appr! oved by t! he EMA throughout the European Union as a once daily oral treatment for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. In July 2010, Swissmedic granted RESOLOR marketing authorization in Switzerland for the treatment of idiopathic chronic constipation in adults. RESOLOR is available in milligram and 2 milligram dose strengths, both for once-daily dosing. At December 31, 2012, RESOLOR was available in six European Union countries. Formulated as a chewable tablet, FOSRENOL is available in 500 milligram, 750 milligram and 1,000 milligram dosage strengths.
XAGRID
XAGRID (anagrelide hydrochloride) is marketed in Europe for the reduction of elevated platelet counts in at-risk ET patients. XAGRID has been granted orphan drug status in the European Union. In the United States, anagrelide hydrochloride is sold by the Company under the name AGRYLIN for the treatment of thrombocythemia secondary to a MPD.
REPLAGAL
REPLAGAL is for the treatment of Fabry disease. Fabry disease is a genetic disorder resulting from a deficiency in the activity of the lysosomal enzyme alpha-galactosidase A, which is involved in the breakdown of fats. REPLAGAL is a human alpha-galactosidase A protein made in human cells that replaces the deficient alpha-galactosidase A with an active enzyme to ameliorate certain clinical manifestations of Fabry disease. At December 31, 2012, REPLAGAL was approved in 46 countries.
ELAPRASE
ELAPRASE is a treatment for Hunter syndrome (also known as Mucopolysaccharidosis Type II or MPS II). Hunter syndrome is a genetic disorder mainly affecting males that interferes with the body's ability to break down and recycle waste substances called mucopolysaccharides, also known as glycosaminoglycans (GAGs). ELAPRASE was approved by the United States Food and Drug Administration and granted marketing authorization by the EMA for the long term treatment of patients with Hunter ! syndrome.! ELAPRASE has been granted orphan drug by both the United States Food and Drug Administration and the EMA. ELAPRASE received approval from the Ministry of Health, Labour and Welfare in Japan. At December 31, 2012, ELAPRASE was approved in 51 countries.
VPRIV
VPRIV is a treatment for Type 1 Gaucher disease. Gaucher disease is an inherited genetic disorder, which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. VPRIV was approved by the United States Food and Drug Administration in February 2010, for the long-term treatment of patients with Type 1 Gaucher disease. The EMA approved the marketing authorization for the use of VPRIV in August 2010. VPRIV was authorized as an orphan medicine through the Centralised Procedure in Europe. At December 31, 2012, VPRIV was approved in 38 countries.
FIRAZYR
FIRAZYR is a peptide-based therapeutic developed for the symptomatic treatment of acute attacks of HAE. In July 2008 the EMA granted marketing authorization throughout the European Union for the use of FIRAZYR for the symptomatic treatment of acute attacks of HAE, and in May 2011 approved FIRAZYR for self-administration after training in subcutaneous injection technique by a healthcare professional. In August 2011, the United States Food and Drug Administration granted marketing approval for FIRAZYR in the United States for treatment of acute attacks of HAE in adults aged 18 and older. After injection training, patients may self-administer FIRAZYR. FIRAZYR has been granted orphan drug by both the United States Food and Drug Administration and the EMA. At December 31, 2012, FIRAZYR was approved in 38 countries globally.
DERMAGRAFT
DERMAGRAFT is a bio-engineered skin substitute that assists in restoring damaged tissue. DERMAGRAFT is indicated for use in the treatment of full-thickness Diabetic foot ulcers (DFU) greater than six weeks in duration, which extend through the dermis, but without tendon, muscle, joint capsu! le, or bo! ne exposure. DERMAGRAFT is approved by the United States Food and Drug Administration as a Class III medical device for the treatment of DFUs. DERMAGRAFT is also approved for the treatment of DFUs in South Africa, Israel and Singapore.
The Company competes with Shionogi & Co., Ltd., Janssen-Cilag, Novartis, Medice, Eli Lilly, Warner Chilcott, Synergy Pharmaceuticals, Inc., ARYx Therapeutics, Theravance, Inc., Sucampo Pharmaceuticals, Inc., Albireo, Actelion Ltd., Protalix BioTherapeutics Inc, Genzyme, CSL Behring, Pharming Group N.V., ViroPharma, Dyax Corporation, Organogenesis, Healthpoint, Soluble System, KCI, Smith & Nephew, Aurobindo and Apotex.
Advisors' Opinion:- [By Matt Egan]
These transactions occur when a U.S. corporation moves its legal headquarters overseas after buying a foreign company that is based in a low-tax country. Medtronic's (MDT) takeover of Ireland's Covidien (COV) and drug maker AbbVie's (ABBV) plan to move to the U.K. by buying Shire (SHPG) are examples.
No comments:
Post a Comment